search

Active clinical trials for "Hodgkin Disease"

Results 191-200 of 784

Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients

Hodgkin Lymphoma

Molecular analysis identifies residual disease by overcoming the sensitivity of imaging methods and therefore has the potential for integrating with therapy provided by FDG-PET alone. It is a well known fact that tumor DNA circulating in plasma (ctDNA) reflects the mutational profile of tumor cells and can be used to non-invasively detect specific mutations of Hodgkin's lymphoma without the need for microdissecting the histological sample.

Recruiting5 enrollment criteria

Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation

Hodgkin's Disease

The main purpose of this study is to determine if it is possible to put into practice a cardiac screening program for survivors of Hodgkin's disease. In this study, we would also like to screen for cardiac risk factors that can be modified either through life-style changes or medications, to uncover significant abnormal heart findings in which treatments may be needed, and to see if there is a link between cardiac health and quality of life.

Active8 enrollment criteria

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk...

Waldenstrom MacroglobulinemiaChronic Lymphocytic Leukemia3 more

Background: Individuals may be prone to develop blood or lymph node cancers (leukemia or lymphoma) for a variety of reasons, including genetic predisposition to these cancers, environmental exposures or other medical conditions. Studies of people and families at high risk of cancer often lead to clues about their cause that may also be important regarding the sporadic occurrence of these cancers in the general population. Identifying genetic or environmental factors that play a role in the development of these diseases may be important in developing prevention trials, screening programs and treatments. Objectives: Describe the cancers and other conditions in families with blood or lymph node cancer. Find and describe genes that may cause blood and lymph node cancer, and understand how they work in families. Use laboratory methods to try to determine if it is possible to identify who is at highest risk of blood or lymph node cancer. Test how genes act with other factors to alter the risk of disease, its severity or its manifestations in families. Eligibility: Individuals of any age with a personal or family history of a blood or lymph node cancer. Individuals with a personal or family history of medical conditions or environmental exposures that may predispose to blood or lymph node cancer. Design: Participants complete questionnaires about their personal and family medical history and provide consent for researchers to review their medical records and pathology materials related to their care and those of deceased relatives with blood or lymph node cancer, tumors, or other related illnesses for whom they are the legally authorized representative. Participants donate a sample of blood or cheek cells, or a lock of hair for genetic studies. Patients may also be evaluated at the NIH Clinical Center by one or more of the following specialists: cancer doctor or blood specialist, medical geneticist, research nurses or clinical social worker. They may have blood and urine tests and a cheek swab or mouth wash to collect cheek cells. Some patients may also be asked to have x-rays and routine imaging, such as CT scans or ultrasound tests, cell surface markers, skin biopsy, and, with special consents, bone marrow biopsy, MRI or PET scans, apheresis or fluorescein angiography and photography.

Recruiting13 enrollment criteria

Tissue Collection for Studies of Lymph Cancer

Hodgkin DiseaseLymphoma5 more

Background: - Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer. To develop these studies, researchers want to collect samples from people with cancer or precancer conditions of the lymph system. These conditions include multiple myeloma, different types of lymphoma, and adult leukemia/lymphoma. The samples collected will include blood, urine, bone marrow, and tumor and skin tissue. Objectives: - To collect tissue samples to study different types of lymph cancer. Eligibility: - Individuals at least 18 years of age who have a lymphoid cancer or precancer condition. Design: Participants will be screened with a physical exam and medical history. Different samples will be collected for study. Blood samples will be collected at the initial testing. More blood samples will be collected at different treatment points. Other liquid samples include urine, bone marrow, and any abnormal fluid. Tumor tissue and skin tissue biopsies will also be collected for study. Treatment will not be provided as part of this study.

Recruiting26 enrollment criteria

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

LymphomaNon-Hodgkin1 more

The purpose of this study is to characterize the molecular and cell biology of the tumor cells in lymphoma.

Recruiting5 enrollment criteria

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Non-Hodgkin's LymphomaHodgkin's Disease4 more

The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.

Recruiting5 enrollment criteria

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

LymphomaNon-Hodgkin2 more

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Recruiting7 enrollment criteria

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed...

Relapsed Hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma

This trial is to assess the safety & efficacy of the Combination of Pembrolizumab and Lenalidomide in the management of patients with Relapsed Hodgkin Lymphoma.

Terminated41 enrollment criteria

Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge...

Hodgkin Lymphoma

Prospective, multicenter, non-interventional, biological study ancillary to FIL-Rouge clinical trial (NCT03159897) enrolling patients affected by Advanced-stage Hodgkin Lymphoma, ABVD-based upfront treatment in 19 centers in Italy part of Fondazione Italiana Linfomi.

Active30 enrollment criteria

Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

Lymphoma

This research is being done to study a combination of Brentuximab vedotin and Rituximab for the treatment of relapsed Hodgkin's Lymphoma (HL).

Terminated11 enrollment criteria
1...192021...79

Need Help? Contact our team!


We'll reach out to this number within 24 hrs